Holen Sie sich die Stockscreener-App
32.32
1.13%
-0.37
Schlusskurs vom Vortag:
$32.69
Offen:
$32.69
24-Stunden-Volumen:
1.56M
Relative Volume:
0.98
Marktkapitalisierung:
$5.14B
Einnahmen:
$803.07M
Nettoeinkommen (Verlust:
$-358.81M
KGV:
-13.25
EPS:
-2.44
Netto-Cashflow:
$-374.21M
1W Leistung:
+4.12%
1M Leistung:
-1.10%
6M Leistung:
-32.92%
1J Leistung:
-25.75%
1-Tages-Spanne:
$32.00
$32.87
1-Wochen-Bereich:
$30.86
$34.74
52-Wochen-Spanne:
$30.23
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Vergleichen Sie IONS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
32.32 | 5.14B | 803.07M | -358.81M | -374.21M | -2.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Ionis Pharmaceuticals targets multibillion-dollar revenue potential with TRYNGOLZA and new launches - MSN
Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James - Yahoo Finance
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control - BioSpace
Ionis Earnings: Tryngolza Commercial Launch Underway; Shares Very Undervalued - Morningstar
Ionis posts Q4 beat as revenue base widens - MSN
Ionis Pharmaceuticals price target lowered to $38 from $45 at Stifel - MSN
What Analysts Are Saying About Ionis Pharmaceuticals Stock - Benzinga
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus - MSN
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Ionis Continues to Expand Its Cardiology and Neurology Portfolio, Supporting Narrow Moat - Morningstar
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2024 Earnings Call Transcript - Insider Monkey
Ionis stock target cut to $60 by Raymond James - Investing.com India
Ionis presents new data on HAE drug donidalorsen - Investing.com
Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Simply Wall St
Can This New HAE Treatment Transform Patient Care? Key Clinical Data Revealed - StockTitan
Ionis Pharmaceuticals Reports Strong 2024 Results - TipRanks
Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Ionis Pharmaceuticals: Q4 Earnings Snapshot - CT Insider
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Ionis Pharmaceuticals: Positive Sentiment in Earnings Call - TipRanks
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Quotes, Forecast and News Summary - Benzinga
Stifel cuts Ionis Pharmaceuticals target to $38, maintains Hold - Investing.com India
Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval (IONS) - Seeking Alpha
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales - AOL
Ionis Pharma Beats Expectations for Q4 - The Motley Fool
Earnings call transcript: Ionis Pharmaceuticals Q4 2024 surpasses forecasts - Investing.com
Earnings call transcript: Ionis Pharmaceuticals Q4 2024 surpasses forecasts By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Ionis stock gains on Q4 beat (IONS:NASDAQ) - Seeking Alpha
Ionis reports fourth quarter and full year 2024 financial results - BioSpace
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Ionis Pharmaceuticals Q4 Net Loss Widens, Revenue Falls; 2025 Sales Guidance Set - Marketscreener.com
IONIS PHARMACEUTICALS Earnings Results: $IONS Reports Quarterly Earnings - Nasdaq
Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus - Investing.com Nigeria
Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus By Investing.com - Investing.com South Africa
BRIEF-Ionis Pharmaceuticals Q4 Revenue USD 227 Million Vs. IBES Estimate USD 137.6 Million - TradingView
Can Ionis' New Drug Launches Offset Its Revenue Decline? Q4 Earnings Deep Dive - StockTitan
Ionis Pharmaceuticals (IONS): Among Top Insider Stock Buys And Sells In January - Insider Monkey
10 Top Insider Stock Buys And Sells In January - Insider Monkey
Ionis Pharmaceuticals (NASDAQ:IONS) shareholders have endured a 44% loss from investing in the stock five years ago - Simply Wall St
Biogen and Stoke Therapeutics collaborate to develop Dravet syndrome treatment globally - Seeking Alpha
How to Take Advantage of moves in (IONS) - Stock Traders Daily
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS - Nasdaq
Ionis stock rises on FDA, EMA nod for SMA drug dose increase - MSN
Ionis Pharmaceuticals (IONS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Sovran Advisors LLC Makes New $5.62 Million Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ionis Pharmaceuticals Inc-Aktie (IONS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Monia Brett P | Chief Executive Officer |
Feb 04 '25 |
Sale |
31.65 |
38,843 |
1,229,463 |
180,683 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):